Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.

Abstract: Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.

Abstract: Various aspects of the subject technology relate to systems, methods, and machine-readable media for providing an application trusted execution environment. Various aspects may include performing attestation of each application enclave of a plurality of application enclaves for a plurality of applications. Aspects may also include receiving a request from a client. Aspects may also include selecting a load balancer to forward the request to the application enclaves. Aspects may also include determining a sensitivity level of the request that is associated with a secured environment parameter. Aspects may include routing, by an enclave server of the load balancer, the request to an application enclave according to the sensitivity level for execution of an application of the plurality of applications in the application trusted execution environment.

Abstract: Provided are a fully-shielded high-frequency connector and a connector assembly. The fully-shielded high-frequency connector includes an insulating base, a shell, a signal terminal and a shielding conductive stiffener. The insulating base includes an insulating body, a fitting portion and a gland portion, a first through hole structure and a second through hole structure. The signal terminal includes a contact portion, a connection portion and a mounting portion. The shielding conductive stiffener includes a tube structure, a fixing connection structure and a cover plate structure. The shell includes a main body portion, a bonding portion, a fixing portion and a snap portion. The fixing portion is electrically connected to the cover plate structure and an outer conductor of the coaxial cable. The bonding portion and the snap portion cooperate to assemble and fix the insulating base and the shell.

Abstract: Provided are a fully-shielded high-frequency connector and a connector assembly. The fully-shielded high-frequency connector includes an insulating base, a shell, a signal terminal and a shielding conductive stiffener. The insulating base includes an insulating body, a fitting portion and a gland portion, a first through hole structure and a second through hole structure. The signal terminal includes a contact portion, a connection portion and a mounting portion. The shielding conductive stiffener includes a tube structure, a fixing connection structure and a cover plate structure. The shell includes a main body portion, a bonding portion, a fixing portion and a snap portion. The fixing portion is electrically connected to the cover plate structure and an outer conductor of the coaxial cable. The bonding portion and the snap portion cooperate to assemble and fix the insulating base and the shell.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: The present invention provides for a cyclopropane compound having the following chemical formula: wherein ? is —H or —COOR, wherein R is —H or an alkyl group, such as —CH3, —CH2CH3, —(CH2)2—CH3, —(CH2)3—CH3, or —C(CH3)3; ? is each independently wherein at least one ? is and, n is an integer from 3 to 11. A fuel composition comprising the cyclopropane compound thereof and a fuel additive. The present invention also provides for a system or genetically modified host cell capable of producing the cyclopropane compound, and a method for producing the cyclopropane compound.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: The present disclosure discloses a board-to-board RF connector including a male plug and a female socket which are mated. The male plug includes: a male plug insulation body; at least two male plug high-frequency signal terminals arranged on the male plug insulation body; at least two male plug low-frequency signal terminals arranged on the male plug insulation body; a male plug shield terminal located between the male plug low-frequency signal terminals and the male plug high-frequency signal terminals and arranged on the male plug insulation body. In contrast with the conventional technology, it is capable of realizing transmissions of the high-frequency signal and the low-frequency signal, meanwhile, it is also capable of reducing the influence caused by the high frequency signal interferes with the low frequency signal.

Abstract: The present disclosure discloses a board-to-board RF connector including a male plug and a female socket which are mated. The male plug includes: a male plug insulation body; at least two male plug high-frequency signal terminals arranged on the male plug insulation body; at least two male plug low-frequency signal terminals arranged on the male plug insulation body; a male plug shield terminal located between the male plug low-frequency signal terminals and the male plug high-frequency signal terminals and arranged on the male plug insulation body. In contrast with the conventional technology, it is capable of realizing transmissions of the high-frequency signal and the low-frequency signal, meanwhile, it is also capable of reducing the influence caused by the high frequency signal interferes with the low frequency signal.

Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Abstract: An advertising management service allows an advertiser to create an advertisement and associate keywords with the advertisement. The advertising management service submits the advertisement to multiple search engine advertising networks on behalf of the advertiser. Periodically, the advertising management service receives a performance indicator for the keywords from the search engine advertising networks. Using the performance indicator, the advertising management service identifies some of the keywords as low performing keywords. The advertising management service replaces the low performing keywords with new keywords on the multiple search engine advertising networks. The advertising management service may also periodically reallocate a budget for the advertisement among the multiple search engine advertising networks based on the performance indicator.